The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Researchers found that higher ocrelizumab exposure over 10 years was associated with less risk of disability progression in ...

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing ...

A new artificial intelligence (AI) tool called MindGlide was found to accurately calculate MS-related brain damage using a ...

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) ...

Neurologist Stephen Hauser, MD, of the University of California San Francisco, and epidemiology professor Alberto Ascherio, ...

Higher doses of the company’s intravenously delivered multiple sclerosis drug failed to show additional benefit in slowing ...

No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Cullinan Therapeutics rebranded from oncology to immunology+oncology, focusing on CD19 TCEs for autoimmune diseases. Check ...

The UCSF luminary and recipient of the prestigious award has played a pivotal part in identifying the cause of multiple sclerosis, leading to a new generation of game-changing therapies.